Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 3/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP7 | P09237 | 2/20 | 0.41 |
| ▸ | MMP14 | P50281 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13649252 | 0.89 | KDM4E (0.47) | PPARAPPARGMMP9MMP2MMP7 | |
| SCHEMBL3258334 | 0.88 | CA2 (0.50) | PPARAPPARGCA1CA2CA9 | |
| SCHEMBL1845745 | 0.85 | APLNR (0.56) | CA1CA2CA9ALDH1A1APLNR | |
| SCHEMBL13847882 | 0.84 | CA1 (0.41) | PPARAPPARGCA1CA2CA9 | |
| SCHEMBL24054628 | 0.82 | APLNR (0.41) | PPARAPPARGCA1CA2CA9 | |
| SCHEMBL9016830 | 0.82 | NQO1 (0.48) | PPARAPPARGCA1CA2CA9 | |
| SCHEMBL6991225 | 0.81 | CA1 (0.48) | CA1CA2CA9MMP9KDM4E | |
| SCHEMBL17891745 | 0.81 | CA2 (0.44) | PPARAPPARGCA1CA2CA9 | |
| SCHEMBL13527822 | 0.81 | CA2 (0.50) | CA1CA2CA9MMP9KDM4E | |
| SCHEMBL7420399 | 0.81 | CA2 (0.47) | PPARAPPARGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181181-B2 | 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | ALBIREO AB (SE) | 2015-11-10 | — | — | US | disclosed |
| US-20140303175-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | ALBIREO AB (SE) | 2014-10-09 | — | — | US | disclosed |
| US-8785681-B2 | 2-substituted-3-phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel disease | ALBIREO AB (SE) | 2014-07-22 | — | — | US | disclosed |
| EP-2125711-B1 | 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALBIREO AB (SE) | 2013-11-06 | — | — | EP | disclosed |
| US-20110166157-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | ALBIREO AB (SE) | 2011-07-07 | — | — | US | disclosed |
| US-20110021534-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALBIREO AB (SE) | 2011-01-27 | — | — | US | disclosed |
| CN-101790512-A | 2 -substituted- 3 -phenylpropionic acid derivatives and their use in the treatment of inflammatory bowel | ALBIREO AB | 2010-07-28 | — | — | CN | disclosed |
| US-20100022589-A1 | PYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE FOR INHIBITING 11-BETA-HYDROXYSTEROID DEHYDROGENASE | MCCOULL WILLIAM | 2010-01-28 | — | — | US | disclosed |
| EP-2125711-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | Albireo Ab (SE) | 2009-12-02 | — | — | EP | disclosed |
| US-7598293-B2 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20030069308-A1 | Comminuted form of(s)-2-ethoxy -3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid | ASTRAZENECA AB (SE) | 2003-04-10 | — | — | US | disclosed |
| EP-1237854-A1 | COMMINUTED FORM OF (S)-2-ETHOXY -3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| EP-1237856-A1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| US-6288096-B1 | ANTIDIABETIC AGENTS, HYPOTENSIVE AGENTS, AND ANTICHOLESTEROL AGENTS | ASTRAZENECA AB (SE) | 2001-09-11 | — | — | US | disclosed |
| WO-2001040172-A1 | NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001040169-A1 | COMMINUTED FORM OF (S)-2-ETHOXY -3-[4-(2- {4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| EP-0991632-A1 | NEW THIAZOLIDINEDIONE, OXAZOLIDINEDIONE AND OXADIAZOLIDINEDIONE DERIVATIVES | Astra Aktiebolag (SE) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998057941-A1 | NEW THIAZOLIDINEDIONE, OXAZOLIDINEDIONE AND OXADIAZOLIDINEDIONE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1998-12-23 | — | — | WO | disclosed |
| US-4490165-A | Meta-(phenylalkoxy)phenyl-N-methoxy-N-methylurea compounds, methods for preparing same and herbicidal use thereof | AMERICAN CYANAMID COMPANY (US) | 1984-12-25 | — | — | US | disclosed |
| US-4308213-A | Meta-(phenylalkoxy)phenyl-N-methoxy-N-methylurea compounds | AMERICAN CYANAMID COMPANY (US) | 1981-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021534-A1 | 2 -SUBSTITUTED- 3 -PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | TPMT, FABP2, PTGES2 | PPARA 25/4885PPARG 35/4885CA1 3281/4885 |
| US-20030069308-A1 | Comminuted form of(s)-2-ethoxy -3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl]propanoic acid | PCSK7, INSR, CEL | PPARA 19/4885PPARG 250/4885CA1 3645/4885 |
| US-20100022589-A1 | PYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE FOR INHIBITING 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD3B2 | PPARA 718/4885PPARG 707/4885CA1 1705/4885 |
| US-20140303175-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | TPMT, FABP2, PTGES3 | PPARA 19/4885PPARG 25/4885CA1 3164/4885 |
| US-20110166157-A1 | 2-Substituted-3-Phenylpropionic Acid Derivatives and Their Use in the Treatment of Inflammatory Bowel Disease | TPMT, FABP2, PTGES3 | PPARA 19/4885PPARG 25/4885CA1 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.